Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
doi: 10.1016/j.jhep.2023.07.021 9
#Pfizer #NovoNordisk #Metsera #EliLilly #BiotechNews #PharmaDeals #HealthcareInnovation #PharmaNews #ObesityDrugs #GLP1 #Amylin #WeightLossMarket #LifeSciences #PharmaceuticalIndustry #DrugDevelopment #HealthcareTrends #BusinessStrategy #MergersAndAcquisitions #MetabolicHealth #ClinicalResearch #Biopharma #InvestmentNews #RAndD #MedicalInnovation #DrugDiscovery #BiotechInvesting #GlobalPharma #HealthcareBusiness #MarketWatch #InnovationInHealth To view or add a comment, sign in Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk
12 in stock
When participants immune cells were exposed to tuberculosis bacteria in laboratory testing, bacterial growth was reduced in the cells from those taking ReadiSorb and grew in the cells from those taking placebo, suggesting enhanced immune defense activity
10 Lo DM et al
Buenas fuentes son las aves de corral, el pescado, el tofu y las legumbres
US$ 27.70
US$ 22.50
US$ 28.00
US$ 20.43
US$ 28.18
US$ 26.56
US$ 23.01
US$ 25.82
US$ 24.95
